Diamyd Closes European Phase III Study. Nuvilex Announces Favorable Pancreatic Cancer Phase II. Print E-mail
By Staff and Wire Reports   
Wednesday, 01 June 2011 19:01
Below is a look at some of the headlines for companies that made news in the healthcare sector on June 1, 2011.

Diamyd Medical AB (OTC:DMYDY) announced they have decided not to complete theEuropean Phase III follow up study with the antigen-based therapy Diamyd.

The Company reported that its European Phase III study with the antigen based therapy Diamyd did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, although a small positive effect was seen.

Diamyd was well tolerated as demonstrated by a similar number of adverse events in the Diamyd treated groups as well as in the placebo treated group. As part of a planned, longer-term follow-up, patients in the study were being followed for an additional 15 months, aiming to determine the durability of the treatment effect at 30 months. Following comprehensive evaluation of the collected study data, Diamyd Medical has decided not to complete the follow-up period.


Nuvilex Inc (OTC:NVLX), announced the favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer.

The trial demonstrated both efficacy and an improvement in quality of life, due in large part to the reduction in toxicity levels from lower dose chemotherapy. Highlights of the trial include: Results demonstrated a 100% increase in patients’ median survival rate.

The 1-year survival rate was twice that observed with the current gold standard Chemotherapy dose needed was only one-third the normal amount improved quality of life was noted in more than half of the patients.


Also Wednesday:


AdCare Health Systems, Inc. (NYSE Amex: ADK)
, a leading skilled nursing and assisted living provider, has closed the previously announced acquisition of a skilled nursing facility in College Park, Georgia.

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the following upcoming investor conferences:  Jefferies 2011 Global Healthcare Conference in New York, NY. Presentation: 10:00 a.m. EDT on Monday, June 6, 2011.

BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that its Board of Directors has declared a 1 percent stock dividend payable on June 30, 2011, to stockholders of record on June 10, 2011.

BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today issued an update on the growing number and quality of life science organizations using the Company's products.

Caliper Life Sciences, Inc. (NASDAQ:CALP), a leading provider of tools and services for drug discovery and life sciences research, hosted its 2011 annual Customers Owners Group (COG 2011) meeting on May 17 and 18 at its Hopkinton headquarters.

CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company will participate in the Jefferies 2011 Global Healthcare Conference on Thursday, June 9, 2011 at 11:00 AM Eastern time, in New York City.

D. Medical Industries Ltd. (NASDAQ:DMED)
(TASE:DMED) ("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today that its subsidiary, Spring-Set Health Solutions Ltd. (formerly "Medx- Set Ltd."), has been granted U.S. Patent No. 7,951,122, entitled "Infusion set self-occlusion mechanism."

Edwards Lifesciences Corporation (NYSE: EW)
, the global leader in the science of heart valves and hemodynamic monitoring, is scheduled to present at the Goldman Sachs 32nd Annual Global Healthcare Conference at Terranea Resort in Rancho Palos Verdes, California on Wednesday, June 8, 2011.

Esterline Corporation (NYSE: ESL) (www.esterline.com), a leading specialty manufacturer serving aerospace/defense markets, today reported fiscal 2011 second quarter (ended April 29) income from continuing operations of $46.0 million, or $1.47 per diluted share, on sales of $435.3 million.

GeneLink Biosciences, Inc. (OTCBB: GNLK.OB), a leading consumer genomics biotech company, held its Scientific Advisory Board Meeting at Disney's Contemporary Resort Convention Center in Orlando, Florida from May 20-22, 2011.

Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced that it intends to dividend a portion of the shares it receives upon completion of a definitive licensing agreement to license its RapidMist™ buccal drug delivery technologies to Amarantus BioSciences, Inc. (www.amarantus.com), a California-based biotechnology company.

HWI Global, Inc., (OTCBB: HWIC), the Pittsburgh-based clean room design builder, announces completing its proprietary Bio-Gard wall lamination at St. Barnabas Hospital in the Bronx.

Luminex Corporation (NASDAQ:LMNX), today announced it has signed a global sales and distribution agreement with Life Technologies Corporation (NASDAQ:LIFE) for its award-winning MAGPIX multiplexing instrument for analysis of proteins for research use.

MicroHoldings US, Inc. (PINKSHEETS: MCHU) today announced its 1st quarter financials report since the purchase of its two subsidiaries in January 2011.

MMRGlobal, Inc. (OTCBB: MMRF) ("MMR") and VisiInc PLC (FRANKFURT: VZJ) (www.deutsche-boerse.com) have entered into an agreement to launch MMRGlobal's patented consumer and professional health IT products and services, including MMRPro for healthcare professionals (www.mmrprovideos.com) and the MyMedicalRecords Personal Health Record (PHR) (www.mmrvideos.com), on the Visi™ platform utilizing the Vistime product.

Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, is pleased to announce that Jeffrey Gottfurcht's use of the Nutra Pharma drug, Nyloxin™, helped to successfully manage his Rheumatoid Arthritis pain during his recent Mount Everest climb.

Shares of Nuvilex (OTCQB: NVLX) (PINKSHEETS: NVLX) continue to trade significantly higher after the company announced favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer.

Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced that the Company will present at the Jefferies 2011 Global Healthcare Conference on June 8, 2011 at 11:00 a.m. Eastern Time at The Grand Hyatt in New York City.

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today announced financial results for the three months ended March 31, 2011.

Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, today announced that its Board of Directors has terminated the shareholder rights plan, effective May 31, 2011.

Tianyin Pharmaceutical Co., Inc. (NYSE Amex:TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced TPI has received the production license for its anti-diabetic drug Gliclazide Tablets (80 mg formulation) from China's State Food and Drug Administration (SFDA).

Verenium Corporation (Nasdaq:VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will host a live webcast of the Company's Analyst and Investor day on Tuesday, June 7, 2011 from The Four Seasons Hotel in New York City.

Waters Corporation (NYSE:WAT) today introduced the new Waters® ACQUITY UPLC® I-Class System, the highest performing UPLC® system ever engineered taking UltraPerformance LC® separations technology to the next level.

Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011 at 11:00am Eastern Time at the Terranea Resort in Rancho Palos Verdes, California.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter